Risk of pneumonia in patients with gastroesophageal reflux disease: A population-based cohort study

PLoS ONE

Volumn 12, Issue 8, 2017, Pages

  Hsu, Wan Tseng ^a   Lai, Chih Cheng ^b   Wang, Ya Hui ^c   Tseng, Ping Huei ^d   Wang, Kun ^c   Wang, Cheng Yi ^c   Chen, Likwang ^e  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b CHI MEI MEDICAL CENTER   (Taiwan)

^c FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^e NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; ARTICLE; CEREBROVASCULAR ACCIDENT; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; GASTROESOPHAGEAL REFLUX; HIGH RISK PATIENT; HUMAN; HYPERTENSION; INCOME; INFECTION RISK; LIVER; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PNEUMONIA; RISK ASSESSMENT; SEX DIFFERENCE; COMPLICATION; INCIDENCE; TAIWAN;

ADULT; COHORT STUDIES; FEMALE; GASTROESOPHAGEAL REFLUX; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PNEUMONIA; TAIWAN;

EID: 85028427829     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0183808     Document Type: Article

References (21)

1. El-Serag HB, Sweet S, Winchester CC, Dent J. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2014; 63(6):871–80. https://doi.org/10.1136/gutjnl-2012-304269 PMID: 23853213; PubMed Central PMCID: PMCPMC4046948.
2. Morehead RS. Gastro-oesophageal reflux disease and non-asthma lung disease. Eur Respir Rev. 2009; 18(114):233–43. https://doi.org/10.1183/09059180.00002509 PMID: 20956148.
3. Perng DW, Chang KT, Su KC, Wu YC, Wu MT, Hsu WH, et al. Exposure of airway epithelium to bile acids associated with gastroesophageal reflux symptoms: a relation to transforming growth factor-beta1 production and fibroblast proliferation. Chest. 2007; 132(5):1548–56. https://doi.org/10.1378/chest.07-1373 PMID: 17908704.
4. Johnstone J, Nerenberg K, Loeb M. Meta-analysis: proton pump inhibitor use and the risk of community-acquired pneumonia. Alimentary pharmacology & therapeutics. 2010; 31(11):1165–77. Epub 2010/ 03/13. https://doi.org/10.1111/j.1365-2036.2010.04284.x PMID: 20222914.
5. Eom CS, Jeon CY, Lim JW, Cho EG, Park SM, Lee KS. Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis. CMAJ: Canadian Medical Association journal = journal de l’Association medicale canadienne. 2011; 183(3):310–9. Epub 2010/12/22. https://doi.org/10.1503/cmaj.092129 PMID: 21173070; PubMed Central PMCID: PMCPmc3042441.
6. Giuliano C, Wilhelm SM, Kale-Pradhan PB. Are proton pump inhibitors associated with the development of community-acquired pneumonia? A meta-analysis. Expert review of clinical pharmacology. 2012; 5 (3):337–44. Epub 2012/06/16. https://doi.org/10.1586/ecp.12.20 PMID: 22697595.
7. Filion KB, Chateau D, Targownik LE, Gershon A, Durand M, Tamim H, et al. Proton pump inhibitors and the risk of hospitalisation for community-acquired pneumonia: replicated cohort studies with meta-analysis. Gut. 2014; 63(4):552–8. Epub 2013/07/17. https://doi.org/10.1136/gutjnl-2013-304738 PMID: 23856153; PubMed Central PMCID: PMCPmc3963530.
8. Chao C-T, Wang C-Y, Lai C-F, Huang T-M, Chen Y-Y, Kao T-W, et al. Dialysis-requiring acute kidney injury increases risk of long-term malignancy: a population-based study. Journal of Cancer Research and Clinical Oncology. 2014; 140(4):613–21. https://doi.org/10.1007/s00432-014-1600-z PMID: 24519490
9. Shih CJ, Chen YT, Ou SM, Li SY, Chen TJ, Wang SJ. Proton pump inhibitor use represents an independent risk factor for myocardial infarction. International journal of cardiology. 2014; 177(1):292–7. Epub 2014/12/17. https://doi.org/10.1016/j.ijcard.2014.09.036 PMID: 25499395.
10. Austin PC. Double propensity-score adjustment: A solution to design bias or bias due to incomplete matching. Statistical methods in medical research. 2017; 26(1):201–22. Epub 2014/07/20. https://doi.org/10.1177/0962280214543508 PMID: 25038071; PubMed Central PMCID: PMCPMC5302082.
11. Laheij RJ, Sturkenboom MC, Hassing RJ, Dieleman J, Stricker BH, Jansen JB. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA. 2004; 292(16):1955–60. https://doi.org/10.1001/jama.292.16.1955 PMID: 15507580.
12. Gulmez SE, Holm A, Frederiksen H, Jensen TG, Pedersen C, Hallas J. Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. Arch Intern Med. 2007; 167(9):950–5. https://doi.org/10.1001/archinte.167.9.950 PMID: 17502537.
13. Ho SW, Hsieh MJ, Yang SF, Yeh YT, Wang YH, Yeh CB. Risk of Stroke-Associated Pneumonia With Acid-Suppressive Drugs: A Population-Based Cohort Study. Medicine. 2015; 94(29):e1227. Epub 2015/07/23. https://doi.org/10.1097/MD.0000000000001227 PMID: 26200649; PubMed Central PMCID: PMCPMC4603020.
14. Lee SW, Lien HC, Chang CS, Yeh HZ, Lee TY, Tung CF. The impact of acid-suppressing drugs to the patients with chronic obstructive pulmonary disease: A nationwide, population-based, cohort study. Journal of research in medical sciences: the official journal of Isfahan University of Medical Sciences. 2015; 20(3):263–7. Epub 2015/06/26. PMID: 26109973; PubMed Central PMCID: PMCPMC4468231.
15. Lee SW, Lin CH, Lien HC, Lee TY, Yeh HZ, Chang CS. Proton Pump Inhibitors Did Not Increase Risk of Pneumonia in Patients With Chronic Obstructive Pulmonary Disease. Journal of clinical medicine research. 2015; 7(11):880–3. https://doi.org/10.14740/jocmr2322w PMID: 26491501; PubMed Central PMCID: PMC4596270.
16. Ho SW, Tsai MC, Teng YH, Yeh YT, Wang YH, Yang SF, et al. Population-based cohort study on the risk of pneumonia in patients with non-traumatic intracranial haemorrhage who use proton pump inhibitors. BMJ open. 2014; 4(11):e006710. Epub 2014/11/12. https://doi.org/10.1136/bmjopen-2014-006710 PMID: 25384687; PubMed Central PMCID: PMCPMC4244437.
17. Sarkar M, Hennessy S, Yang YX. Proton-pump inhibitor use and the risk for community-acquired pneumonia. Annals of internal medicine. 2008; 149(6):391–8. Epub 2008/09/17. PMID: 18794558.
18. Vakil N. Acid inhibition and infections outside the gastrointestinal tract. The American journal of gastro-enterology. 2009; 104 Suppl 2:S17–20. Epub 2009/03/06. https://doi.org/10.1038/ajg.2009.47 PMID: 19262541.
19. Aybay C, Imir T, Okur H. The effect of omeprazole on human natural killer cell activity. Gen Pharmacol. 1995; 26(6):1413–8. PMID: 7590140.
20. Scaringi L, Cornacchione P, Fettucciari K, Rosati E, Rossi R, Marconi P, et al. Activity inhibition of cyto-lytic lymphocytes by omeprazole. Scand J Immunol. 1996; 44(3):204–14. PMID: 8795713.
21. Yoshida N, Yoshikawa T, Tanaka Y, Fujita N, Kassai K, Naito Y, et al. A new mechanism for anti-inflammatory actions of proton pump inhibitors—inhibitory effects on neutrophil-endothelial cell interactions. Alimentary pharmacology & therapeutics. 2000; 14 Suppl 1:74–81. PMID: 10807407.